Rocuronium Bromide (Rocuronium Bromide) Patent Expiration, LOE Window & CMS Spending

Rocuronium Bromide (Rocuronium Bromide) by Fresenius Kabi: FDA Orange Book LOE 2039-07-22, 21 AB generics, $30.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN217472 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-07-22
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors21
2024 CMS Total Public Spend$30.3M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$30.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.